Lilly will oversee clinical development, manufacturing, regulatory affairs, and commercialisation of any resulting therapies. Credit: Michael Vi / Shutterstock.com. Repertoire Immune Medicines has collaborated with Eli Lilly and Company to develop tolerising therapies to treat several autoimmune diseases. The partnership will focus on creating treatments intended to restore immune homeostasis and deliver durable remission for patients, avoiding the generalised immune suppression associated with

Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs). NEWARK, DE, UNITED STATES, February 3, 2026 / EINPresswire.com / -- Biosion , Inc. (“Biosion”), a global, clinical-stage biotechnology company developing innovative antibody-based therapeutics, today announced that the first patient has been dosed in a Phase 1a/1b Investigator-Initiated Trial (IIT) evaluating BSI-082 , a highly differentiated, fully human anti-SIRPα mon

NESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present new safety and efficacy data from the GA Depot Phase II study in primary progressive multiple sclerosis (PPMS) at the ACTRIMS Forum 2026 Conference, to take place February 5-7, 2026, in San Diego, CA. GA Depot is a long-acting injection version of the approve

Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy and a significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM) Interim readout expected in 2H 2026 Feb. 03, 2026 -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced it had dosed the first patient in the Phase 2/3 IIMPACT

GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to extend cash runway through Q4 2026 Feb. 03, 2026 -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK

Feb. 3, 2026 -- Imbed Biosciences, a leader in advanced synthetic antimicrobial and tissue regeneration solutions, today announced a strategic investment from BioLab Holdings Inc. This investment is set to significantly expand Imbed Biosciences' reach within the US market, particularly in the MD office setting, and accelerate the development of its proprietary SAM™ Antimicrobial Technology platform to minimize wound care complications. "The strategic investment from BioLab Holdings marks a pivo

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Biogen’s litifilimab (BIIB059) for cutaneous lupus erythematosus (CLE), a chronic autoimmune skin condition. This designation aims to expedite the development and review of medicines for serious conditions. The FDA based its decision on comprehensive data, including findings from the Phase II LILAC study. Results from this trial indicated that litifilimab reduced skin disease activity in patients with CLE

Sensorion has announced a €60m ($71.9m) reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share to advance the development of its gene therapy pipeline. The financing includes a €20m strategic investment from Sanofi and €40m from existing and new investors such as Artal (advised by Invus), Redmile Group, Cormorant Asset Management, Sofinnova Partners, Sphera Healthcare, and Coastlands Capital. Settlement of the offering is expected around 30 January 2026, s

Februari 2, 2026 - Immedica today announces the results from a phase 3 clinical study Loargys® in children below 2 years of age with arginase 1 deficiency (ARG1-D). ARG1-D is an autosomal recessive urea cycle disorder (UCD) characterized by chronic hyperargininemia, leading to progressive spasticity, developmental delay, and seizures. Available treatment before Loargys involved a strict protein-restricted diet, essential amino acid supplementation, and symptom management. Despite these interven

- SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million upfront payment and will be eligible to receive development and commercialization milestone payments, totaling up to $1.5 billion, plus tiered royalties - Genentech will be responsible for the subsequent clinical development and commercialization globally Feb. 2, 2026 -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today